The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission
about
Acute lymphoblastic leukaemiaAllogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioningAntigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomabAllogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative GrouSurvival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia.The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemiaComparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALLRisk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remissionResults from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.Myeloid Leukemias and Virally Induced Lymphomas in Miniature Inbred Swine: Development of a Large Animal Tumor Model.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsCellular therapies in acute lymphoblastic leukemiaPediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remissionImpact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors.UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions.Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia.The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia.Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults.Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation.Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
P2860
Q24602387-D1DA840B-816C-4371-89DC-39A6D5AE6701Q26795740-55CF5185-6759-4186-9423-08A460316904Q27013710-504BEB48-BA45-4225-88F4-7FAC3D50E831Q30577948-8C836CB1-28D1-459B-93B6-C144970F99D2Q31143348-8C679DAE-81B7-4E62-8949-E3298AE8223EQ33605181-AAD13669-BC46-410C-8404-D21BB2376BDDQ33816017-BA011309-96F2-42FB-ADAF-241516904651Q34360641-1BFE1270-D98E-4FE7-A41F-B7BB6D28A8F2Q34532041-E2FD9CE4-AA33-4E70-A860-6387DA3649CEQ34664111-A3A7947D-B799-44D6-9F09-87FD214822D5Q35057041-F68FA3A5-95B5-4A34-BC97-F3EFE04804C9Q35136563-61BAC765-CC26-482E-9057-FC6570B02397Q35199893-A28E8E7D-9E72-45D4-8464-FB56FACE7F58Q35640788-47F5E621-165D-4214-AD13-3A1A55A8B924Q36023505-6CA6555E-7004-4EF6-99E3-C9C89519824EQ36036328-B8905330-0EF7-4030-B9D3-B615217F106BQ36300656-44BB06AA-F52F-40BA-925C-87B397EEE000Q36461915-9AD52AC4-3CC5-4C10-92D3-334645558CEDQ36552098-BC3B9584-D577-4050-B332-69E0432FFAE4Q36609579-4BF7B6CF-F62A-4ED3-8996-F0B5BABE0D8DQ36687119-950B69D3-D571-44C7-A25B-25D0907355C4Q36892609-36BB4D33-50D4-4ECC-B157-E09E5B092CFEQ37079011-85E68685-3CA7-4DC1-83A3-488E92E47BAFQ37552039-54BD2AED-17EB-49E4-8180-0C3827161C5BQ37564762-80712749-F327-4CEC-8500-35995C7D4B40Q37632798-158CC60C-DE39-4BB2-9578-9C69F32EB8E4Q37813013-5B7A8CC4-DFFC-451F-9BA6-590211944CE7Q37919867-DDD8B166-C35A-43A9-93F9-9F1CFC61AC47Q37992837-11132ECF-B6F3-4FBF-B4A8-9F11A3BF978CQ38087853-3C2697FA-DB66-4964-BC7D-9D8F2A1CA932Q38098957-095DEC94-DFEA-4FB5-B8F8-05CD162F5C83Q38133244-FC9B42DC-5584-4AFD-945F-7488E5852A7BQ38226100-1D336704-2603-41F8-A685-E85AD7BCC478Q38488058-8A545583-AAEC-4AB8-9098-EE43ECAFCC9CQ38698520-50730B94-CE5A-40A4-89DB-BB84B39B4BF4Q38777538-D8F57414-4467-4822-8CE7-222F18C4865BQ38953608-D0E40A11-9EE1-4215-98BB-CC8DA5F54682Q39157279-283C49A0-5842-4F9F-A20C-76DE241AFEE7Q39158433-CF3F0CB8-5C10-41E4-A459-EB73292D932EQ39212390-D8A32CFE-AAE1-4B41-B95C-FA420292BD1E
P2860
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The outcome of full-intensity ...... and second complete remission
@ast
The outcome of full-intensity ...... and second complete remission
@en
The outcome of full-intensity ...... and second complete remission
@nl
type
label
The outcome of full-intensity ...... and second complete remission
@ast
The outcome of full-intensity ...... and second complete remission
@en
The outcome of full-intensity ...... and second complete remission
@nl
prefLabel
The outcome of full-intensity ...... and second complete remission
@ast
The outcome of full-intensity ...... and second complete remission
@en
The outcome of full-intensity ...... and second complete remission
@nl
P2093
P2860
P50
P1433
P1476
The outcome of full-intensity ...... and second complete remission
@en
P2093
Biju George
Daniel J Weisdorf
David A Rizzieri
David I Marks
Edward Copelan
H Jean Khoury
Joerg Halter
Joseph H Antin
Mitchell Sabloff
Philip McCarthy
P2860
P304
P356
10.1182/BLOOD-2010-01-264077
P407
P577
2010-04-19T00:00:00Z